Table 1.
Characteristics of 719 patients treated with MCN
| Characteristic | No. or mean ± SD |
|---|---|
| Sex (male:female) | 474:245 |
| Age (years) | 67.6 ± 9.1 |
| Hepatitis (B/C/BC/no B no C) | 92/525/11/91 |
| Serum albumin (g/dl) | 3.7 ± 0.5 |
| Total bilirubin (mg/dl) | 1.0 ± 0.7 |
| Prothrombin activity (%) | 79 ± 15 |
| Child–Pugh class (A/B/C) | 503/216/0 |
| Tumor size (mm) | 26.9 ± 11.9 |
| Range(mm) | 7.9–80.0 |
| Tumor <2 cm, n (%) | 201 (28.0) |
| 2 ≤ Tumor < 3 cm, n (%) | 301 (41.9) |
| 3 ≤ Tumor < 5 cm, n (%) | 182 (25.3) |
| Tumor ≥5 cm, n (%) | 35 (4.8) |
| Tumor number | 2.51 ± 2.04 |
| Range | 1–12 |
| 1, n (%) | 335 (46.6) |
| 2 or 3, n (%) | 216 (30.0) |
| ≥4, n (%) | 168 (23.4) |
| TNM stage by LCSGJ (I/II/III/IV) | 111/317/279/12 |
| Serum AFP (ng/ml) | 614.9 ± 4411.5 |
| L3 (%) | 11.2 ± 18.5 |
| DCP (mAu/ml) | 675.6 ± 3376.0 |
Data are given as means ± standard deviation
LCSGJ Liver Cancer Study Group of Japan, AFP serum α-fetoprotein, L3 lectin-reactive α-fetoprotein, DCP plasma des-γ-carboxy-prothrombin